Beyond Antiplatelet Therapy: Advances in CAD/PAD Management
Antiplatelet therapy, the long-running standard of care for the management of stable coronary artery disease (CAD) and peripheral artery disease (PAD), is often insufficient to prevent secondary cardiovascular events and mortality. This initiative will explore the use of dual pathway inhibition (with specific agents and doses of anticoagulation therapy plus antiplatelet therapy), as a potential new treatment paradigm to enhance cardio protection across a wide range of patients with CAD and/or PAD.
This initiative is jointly provided by Paradigm Medical Communications, LLC and Educational Review Systems, Inc.
The Science Behind Dual Pathway Inhibition in CAD/PAD
CAD and Multiple Risk Factors
PAD After Lower Extremity Revascularization